Literature DB >> 11090955

Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats.

S Kimura1, H Saito, M Minami, H Togashi, N Nakamura, M Nemoto, H S Parvez.   

Abstract

Stroke-prone spontaneously hypertensive rats (SHRSP) are the best model for essential hypertension and stroke. In this study, one investigated whether SHRSP might be a useful animal model for vascular dementia. An impairment of learning-memory function was found in SHRSP. A disturbance in circadian rhythm after stroke in SHRSP was clarified. Desynchronization of light and dark alternation cycles and abnormal rhythm were also demonstrated. These observations point to the possibility that the decreased passive avoidance response observed in SHRSP might be similar to the phenomenon of memory impairment in patients with vascular dementia. The behavioral changes in ambulation in SHRSP, including the desynchronization between light and dark alternation cycles and the abnormal rhythm before death, might correspond to the behavioral changes associated with the delirium-state observed in patients with dementia. Cerebral cortex levels of acetylcholine and choline in SHRSP decreased significantly as compared with the Wistar Kyoto rats (WKY) control group. Hippocampal levels of acetylcholine and choline in SHRSP decreased significantly as compared with those in WKY. Moreover, a correlation between passive avoidance response latency and hippocampal acetylcholine levels was observed. These findings suggest that decreased acetylcholine levels in both the cerebral cortex and the hippocampus may be related to the impairment of learning-memory function and abnormal behavior. In SHRSP, increases in blood viscosity, hematocrit and fibrinogen might produce the formation of thrombus and induce cerebral infarction. Some histopathological findings caused by cerebrovascular disorder in human brain very similar to those observed in the SHRSP brain. On the other hand, so called 'senile changes' were detected only in the human case, and not observed in the SHRSP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090955     DOI: 10.1016/s0300-483x(00)00312-7

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  28 in total

1.  Cognitive function and cholinergic transmission in patients with subcortical vascular dementia and microbleeds: a TMS study.

Authors:  Raffaele Nardone; Pierpaolo De Blasi; Martin Seidl; Yvonne Höller; Francesca Caleri; Frediano Tezzon; Gunther Ladurner; Stefan Golaszewski; Eugen Trinka
Journal:  J Neural Transm (Vienna)       Date:  2011-04-24       Impact factor: 3.575

2.  Vascular cognitive impairment.

Authors:  Laura Pedelty; David L Nyenhuis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

3.  Carotid artery stenosis in hypertensive rats impairs dilatory pathways in parenchymal arterioles.

Authors:  Nusrat Matin; Courtney Fisher; William F Jackson; Janice M Diaz-Otero; Anne M Dorrance
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-08-25       Impact factor: 4.733

Review 4.  White matter hyperintensities, cognitive impairment and dementia: an update.

Authors:  Niels D Prins; Philip Scheltens
Journal:  Nat Rev Neurol       Date:  2015-02-17       Impact factor: 42.937

Review 5.  The effects of hypertension on the cerebral circulation.

Authors:  Paulo W Pires; Carla M Dams Ramos; Nusrat Matin; Anne M Dorrance
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-12       Impact factor: 4.733

Review 6.  Cholinesterase inhibitors and vascular dementia: another string to their bow?

Authors:  Roger Bullock
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Clinical pharmacokinetics of galantamine.

Authors:  Martin R Farlow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 8.  Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.

Authors:  Juan Wang; Hai-Yan Zhang; Xi-Can Tang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

9.  Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.

Authors:  Gary Small; Timo Erkinjuntti; Alexander Kurz; Sean Lilienfeld
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 10.  Vascular dementia: prevention and treatment.

Authors:  Catherine McVeigh; Peter Passmore
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.